Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874549 · ClinicalTrials.gov registry record · Phase 1
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
A Phase 1 study of Meningococcal Infections and Meningococcal Meningitis, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
- 6
- Study locations
NCT00874549 is a Phase 1 study of Meningococcal Infections and Meningococcal Meningitis that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 216 participants, below the 767-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (72% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00874549, a Phase 1 study of Meningococcal Infections and Meningococcal Meningitis, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
- 6
- Study locations
Study Summary
Safety: To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination with either Menactra® vaccine or Menomune® vaccine. Immunogenicity: To evaluate the immune response to serogroups A, C, Y, and W-135 in each of the four study groups.
Conditions Studied
Interventions
- BIOLOGICAL Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide
- BIOLOGICAL Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Study Locations (6)
Washington
- - Seattle
- - Spokane
Arizona
- - Scottsdale
Kentucky
- - Bardstown
New Mexico
- - Albuquerque
Utah
- - West Jordon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874549
The ClinicalTrials.gov registry entry for NCT00874549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 767-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (72% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Meningococcal Infections appearing as the primary indexed condition, and to 2 interventions - of which Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide is the first listed.
NCT00874549 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Washington, Arizona, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00874549 about?
NCT00874549 is a clinical study titled "Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years". Safety: To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination with either Menactra® vaccine or Menomune® vaccine. Immunogenicity: To evaluate the immune response to serogroups...
What is the current status of trial NCT00874549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2007-10. Estimated completion is 2008-10.
What conditions does trial NCT00874549 study?
This clinical trial studies the following conditions: Meningococcal Infections, Meningococcal Meningitis.
What interventions are being tested in trial NCT00874549?
The interventions under investigation include: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide (BIOLOGICAL), Menactra®: Polysaccharide Diphtheria Toxoid Conjugate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00874549?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874549 being conducted?
This trial has 6 study locations across Arizona, Kentucky, New Mexico, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningococcal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azithromycin for Meningococcal Carriage
RECRUITING · Phase 2
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.